Engineered immune cells take aim at Hard-to-Treat leukemia
NCT ID NCT04219163
First seen Oct 31, 2025 · Last updated May 25, 2026 · Updated 29 times
Summary
This study tests a new treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are modified in the lab to recognize and attack AML cells carrying a protein called CLL-1. The goal is to see if this cell therapy is safe and can shrink the cancer, potentially as a bridge to a stem cell transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.